Neurocrine /
Soleno
Neurocrine finishes its takeover of Soleno after tender offer succeeds
Source for the buyer and target: Neurocrine Biosciences, Inc.
For the buyer and target.
“Purchaser was merged with and into Soleno, and Soleno continued as the surviving corporation and as a direct wholly owned subsidiary of Neurocrine.”
Published 18 May 2026
Open the sourceWhat happened
Neurocrine has completed its acquisition of Soleno. A tender offer at $53.00 per share in cash drew about 88.9% of Soleno's outstanding common stock, and those shares were accepted for payment. [01]
A merger on May 18, 2026 followed, leaving Soleno as a direct, wholly owned subsidiary of Neurocrine. Shares not tendered were converted into the right to receive the same $53 per share in cash. The deal carried a total equity value of $2.9 billion. [01]
The purchase adds VYKAT XR, an approved treatment for hyperphagia in Prader-Willi syndrome, to Neurocrine's commercial portfolio. Soleno's stock is no longer listed on the Nasdaq Capital Market. [01]
The source
Everything on this page comes from the source below, quoted word for word.
Neurocrine finishes its takeover of Soleno after tender offer succeeds
This document is the source for the companies, stage, figure and people on this page.
Open the sourceTimeline
Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.
Closed
“A merger on May 18, 2026 followed, leaving Soleno as a direct, wholly owned subsidiary of Neurocrine”
Open the source
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Get ProAlready a member? Sign in
Pro is open to everyone.
By email · Weekly